Mega Lifesciences (MEGA) investor relations material

Executive summary

• Operating revenue for 1H26 grew 12.5% year-over-year, driven by double-digit growth in both branded products and distribution segments.

• Gross margin improved to 52.0% from 50.5% in 1H25, reflecting stronger segmental performance.

• EBITDA rose 33.8% year-over-year to THB 1,613mn, and reported net profit increased 33.1% to THB 1,119mn.

• Adopted amendments to TAS 21 regarding foreign exchange rates, impacting assets and equity, especially due to Myanmar Kyat restrictions.

• Acquired full control of Mega MSN Pte Ltd. in March 2026, consolidating its assets.

Financial highlights

• Mega We Care™ segment revenue grew 11.9% year-over-year, with Southeast Asia contributing 73.3% of segment revenue.

• Maxxcare™ distribution revenue increased 11.3% year-over-year, supported by improved conditions in Myanmar.

• Segment results before tax for the six months ended 30 June 2026: Brands THB 1,403m, Distribution THB 241m, OEM THB 74m; total THB 1,719m, up from THB 1,552m year-over-year.

• Consolidated net profit after tax for the six months: THB 1,119m, up from THB 841m year-over-year.

• Total consolidated assets as of 30 June 2026: THB 16,026m, up from THB 15,759m at year-end 2025.

Outlook and guidance

• Strategic plan targets doubling consolidated net profits by 2030 from the 2025 base year.

• Healthy pipeline of nearly 100 products, with over 80 launched between 2022-25, expected to drive future sales.

• Entry into Indonesia via manufacturing acquisition to contribute meaningfully from 2027.

• Board approved interim dividend of THB 0.85 per share (THB 741.09m) to be paid in September 2026.

• Planned THB 2.6bn investment in new manufacturing facilities in Vietnam, Myanmar, and Indonesia from 2026-2028.